CheckMate 816: Neoadjuvant nivolumab plus chemotherapy provides long-term OS benefit in patients with early-stage NSCLC
Lung, Respiratory and Thoracic Cancer
WCLC 2025
Related content
WCLC 2025
Lung, Respiratory and Thoracic Cancer
EMPOWER-Lung 3: Cemiplimab plus chemotherapy provide sustained survival benefits in patients with advanced NSCLC
ESMO 2025
Gastrointestinal Cancer
CheckMate 8HW: Nivolumab plus ipilimumab provides clinically meaningful benefits over nivolumab alone in MSI-H/dMMR-positive mCRC
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Comparison of long-term survival between nivolumab plus ipilimumab with chemotherapy and pembrolizumab with chemotherapy in advanced non-small cell lung cancer: A multicenter retrospective cohort study
★ 1
Recommended by
Dr Martin Frey, Faculty Member
★ 1
Recommended by
Dr Marcus Hesse, Faculty Member
Lung Cancer
Kinehara Y, Matsumoto K, Shiroyama T, Komuta K, Tamiya M, Nishino K, Tamiya A, Kuge T, Uchida J, Suzuki H, Yamamoto S, Tobita S, Niki T, Tetsumoto S, Morimura O, Osa A, Minami T, Nagatomo I, Takeda Y, Kijima T, Kumanogoh A
doi: 10.1016/j.lungcan.2026.109336
ESMO 2025
Breast Cancer
monarchE: Abemaciclib plus ET versus ET alone shows proven OS benefit in patients with HR+/HER2− node-positive, high-risk early breast cancer
Lung, Respiratory and Thoracic Cancer
Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic Non-small Cell Lung Cancer Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1
J Thorac Oncol
Peters S, Regan MM, Paz-Ares LG, Reck M, Borghaei H, O'Byrne KJ, Brahmer JR, Penrod JR, Li J, Tracy L, Yuan Y, Bushong J, Lee A, Eccles LJ, Ray S, Ramalingam SS
doi: 10.1016/j.jtho.2025.05.019
SABCS 2025
Breast Cancer
NATALEE: Long-term data show sustained clinical benefit with ribociclib plus an NSAI in HR-positive, HER2-negative early breast cancer
Lung, Respiratory and Thoracic Cancer
Overall Survival with Neoadjuvant Nivolumab plus Chemotherapy in Lung Cancer
N Engl J Med
Forde PM, Spicer JD, Provencio M, Mitsudomi T, Awad MM, Wang C, Lu S, Felip E, Swanson SJ, Brahmer JR, Kerr K, Taube JM, Ciuleanu TE, Tanaka F, Saylors GB, Chen KN, Ito H, Liberman M, Martin C, Broderick S, Wang L, Cai J, Duong Q, Meadows-Shropshire S, Fiore J, Bhatia S, Girard N, CheckMate 816 Investigators
doi: 10.1056/NEJMoa2502931
Gastrointestinal Cancer
Does the benefit of neoadjuvant chemotherapy at six months predict long-term outcomes in colon or rectal cancer? A meta-analysis of randomised studies
Cancer Treat Rev
Socha J, Michalski W, Glynne-Jones R, Glimelius B, Bujko K
doi: 10.1016/j.ctrv.2025.103020
Gastrointestinal Cancer
Adjuvant FLOT provides survival benefit for oesophagogastric junction and gastric adenocarcinoma patients with low tumour regression after neoadjuvant chemotherapy
Int J Cancer
Kraemer M, Wirsik NM, Alakus H, Schloesser HA, Fuchs H, Schroeder W, Bruns CJ, Lyu SI, Baehr F, Zander T, Quaas A
doi: 10.1002/ijc.70048